Manuscript Submission Information Manuscripts should be submitted online at by registering and logging in to this website . Once you are registered, click here to go to the submission form . Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Personally, I think that Paleo, as a personal choice, can include a spectrum, or many degrees of interpretations and adherences, and choosing whether or not to include salt is something I would include as a discretionary item, along with dairy. Salt may very well not be, strictly speaking, part of “the” Paleo diet, but I think a paleo adherent could make a reasoned case for salting their food to taste. The basic idea of paleo will continue to evolve and branch as people choose to take their own views, sometimes making it more restrictive (raw paleo) or less (primal), but I would suggest that these debates are intra-community debates that have less significance than extra-community debates (those we all continue to have with the heart-healthy whole grains, low fat crowds). But thanks for weighing in on this one and including some useful information so that folks can make more informed choices.
Patients with CKD did not differ significantly from the control group with respect to age, gender and body mass ( Table 1 ). As presented in Figure 2 , patients with CKD had -fold greater plasma levels of MBG as compared to that in the control group. When EO concentrations were determined by an assay based on anti-ouabain antibody M, levels of this hormone in patients with CKD were not different from control values but the assay based on antibody S, which exhibits cross-immunoreactivity with bufadienolides, detected an almost 2-fold elevation of EO in patients with chronic renal failure. The assay based on Digibind did not detect immunoreactivity in individual samples of plasma from both CKD and control groups (data not shown). When samples from each group were pooled and concentrated 10-fold, levels of CTS measured by Digibind fluoroimmunoassay in patients with CKD were increased 4-fold versus that in control group, which was proportional to the observed increase in the plasma levels of MBG seen in these patients ( Figure 2D ). In order to confirm that anti-ouabain antibody S indeed exhibits greater cross-reactivity with MBG as compared to anti-ouabain antibody M, we pooled aliquots of control plasma, spiked it with MBG ( Figure 2E ), extracted them on C18 SepPak cartridges and determined levels of MBG and ouabain-like immunoreactivity using both anti-ouabain antibodies. As presented in Figure 2F , anti-ouabain antibody S detected elevation in the levels of MBG much better than anti-ouabain antibody M.